Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy
- 26 May 2010
- journal article
- review article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 26 (8) , 568-577
Abstract
BRCA1 and BRCA2 mutation carriers have a 54–85% and 45% lifetime risk of developing breast cancer, respectively, and a 18–60% and 11–27% lifetime risk of developing ovarian cancer, respectively. Oral contraceptives (OCs) significantly reduce the risk of ovarian cancer also in BRCA1/BRCA2 mutation carriers. The association between OC use and breast cancer risk in these women is controversial. Some studies showed a modestly increased risk especially among BRCA1 mutation carriers. The risk appears to be greater for women who took OCs for at least 5 years and who took OCs before the age of 30 years. Other studies reported that duration of use before first full-term pregnancy has a positive association with breast cancer risk. Salpingo-oophorectomy reduces the risk of coelomic epithelial cancer of 80–95% and the risk of breast cancer of approximately 50%. BRCA1 and BRCA2 mutation carriers should be encouraged to undergo prophylactic bilateral salpingo-oophorectomy at the age of 35–40 years or when childbearing is complete. Short-term use of hormone replacement therapy may relieve menopausal symptoms and does not appear to affect the breast cancer risk reduction obtained with salpingo-oophorectomy.Keywords
This publication has 93 references indexed in Scilit:
- Genetics: Breast Cancer as an ExemplarNursing Clinics of North America, 2009
- Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation CarriersJNCI: Journal of the National Cancer Institute, 2009
- Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort studyBreast Cancer Research and Treatment, 2007
- Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004British Journal of Cancer, 2006
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast CancerJNCI: Journal of the National Cancer Institute, 2003
- Breast cancer and specific types of oral contraceptives: A large Norwegian cohort studyInternational Journal of Cancer, 2003
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003
- Hormonal content and potency of oral contraceptives and breast cancer risk among young womenBritish Journal of Cancer, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002